High materiality7/10
ArriVent Biopharma price target lowered to $18 from $45 at Guggenheim
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Guggenheim lowers AVBP target to $18; price $15.09; upside remains; bullish setup.
- Target $18; price $15.09; bullish setup.
Key facts
- 01
Target: $18
- 02
Posted price: $15.09
- 03
Analyst firm: Guggenheim
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.